These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 33831021)
1. Investigating the procurement system for understanding seasonal influenza vaccine brand availability in Europe. Stuurman AL; Rizzo C; Haag M PLoS One; 2021; 16(4):e0248943. PubMed ID: 33831021 [TBL] [Abstract][Full Text] [Related]
2. The impact of vaccine procurement methods on public health in selected European countries. Wilsdon T; Lawlor R; Li L; Rafila A; García Rojas A Expert Rev Vaccines; 2020 Feb; 19(2):123-132. PubMed ID: 31990601 [No Abstract] [Full Text] [Related]
3. Brand-specific influenza vaccine effectiveness estimates during 2019/20 season in Europe - Results from the DRIVE EU study platform. Stuurman AL; Biccler J; Carmona A; Descamps A; Díez-Domingo J; Muñoz Quiles C; Nohynek H; Rizzo C; Riera-Montes M; Vaccine; 2021 Jun; 39(29):3964-3973. PubMed ID: 34092427 [TBL] [Abstract][Full Text] [Related]
4. Vaccine effectiveness against laboratory-confirmed influenza in Europe - Results from the DRIVE network during season 2018/19. Stuurman AL; Bollaerts K; Alexandridou M; Biccler J; Díez Domingo J; Nohynek H; Rizzo C; Turunen T; Riera-Montes M; Vaccine; 2020 Sep; 38(41):6455-6463. PubMed ID: 32778474 [TBL] [Abstract][Full Text] [Related]
5. Factors driving choices between types and brands of influenza vaccines in general practice in Austria, Italy, Spain and the UK. Stuurman AL; Ciampini S; Vannacci A; Bella A; Rizzo C; Muñoz-Quiles C; Pandolfi E; Liyanage H; Haag M; Redlberger-Fritz M; Bonaiuti R; Beutels P PLoS One; 2021; 16(6):e0252836. PubMed ID: 34129638 [TBL] [Abstract][Full Text] [Related]
6. Brand-specific estimates of influenza vaccine effectiveness for the 2021-2022 season in Europe: results from the DRIVE multi-stakeholder study platform. Stuurman AL; Carmona A; Biccler J; Descamps A; Levi M; Baum U; Mira-Iglesias A; Bellino S; Hoang U; de Lusignan S; Bonaiuti R; Lina B; Rizzo C; Nohynek H; Díez-Domingo J; Front Public Health; 2023; 11():1195409. PubMed ID: 37546295 [TBL] [Abstract][Full Text] [Related]
7. Challenges and changes: immunization program managers share perspectives in a 2012 national survey about the US immunization system since the H1N1 pandemic response. Seib K; Chamberlain A; Wells K; Curran E; Whitney EA; Orenstein WA; Hinman AR; Omer SB Hum Vaccin Immunother; 2014; 10(10):2915-21. PubMed ID: 25483633 [TBL] [Abstract][Full Text] [Related]
8. National community pharmacy NHS influenza vaccination service in Wales: a primary care mixed methods study. Evans AM; Wood FC; Carter B Br J Gen Pract; 2016 Apr; 66(645):e248-57. PubMed ID: 26965025 [TBL] [Abstract][Full Text] [Related]
9. Assessing optimal use of the standard dose adjuvanted trivalent seasonal influenza vaccine in the elderly. Thorrington D; van Leeuwen E; Ramsay M; Pebody R; Baguelin M Vaccine; 2019 Apr; 37(15):2051-2056. PubMed ID: 30871927 [TBL] [Abstract][Full Text] [Related]
10. Stakeholders' perceptions of 10years of the Global Action Plan for Influenza Vaccines (GAP) - Results from a survey. Nannei C; Goldin S; Torelli G; Fatima H; Kumar K; Bubb-Humfryes O; Stenson B; Sparrow E Vaccine; 2016 Oct; 34(45):5393-5399. PubMed ID: 27646029 [TBL] [Abstract][Full Text] [Related]
11. Influenza vaccination coverage rates in 5 European countries: a population-based cross-sectional analysis of the seasons 02/03, 03/04 and 04/05. Müller D; Szucs TD Infection; 2007 Oct; 35(5):308-19. PubMed ID: 17885730 [TBL] [Abstract][Full Text] [Related]
12. Pricing of HPV vaccines in European tender-based settings. Qendri V; Bogaards JA; Berkhof J Eur J Health Econ; 2019 Mar; 20(2):271-280. PubMed ID: 30051152 [TBL] [Abstract][Full Text] [Related]
13. Descriptive investigation of the recording of influenza vaccination details on The Health Information Network database. Hall GC; Hill F Pharmacoepidemiol Drug Saf; 2014 Jun; 23(6):595-600. PubMed ID: 24123471 [TBL] [Abstract][Full Text] [Related]
14. Influenza vaccination coverage rates in five European countries-a population-based cross-sectional analysis of two consecutive influenza seasons. Szucs TD; Müller D Vaccine; 2005 Oct; 23(43):5055-63. PubMed ID: 16046035 [TBL] [Abstract][Full Text] [Related]
15. Influenza vaccination in the Americas: Progress and challenges after the 2009 A(H1N1) influenza pandemic. Ropero-Álvarez AM; El Omeiri N; Kurtis HJ; Danovaro-Holliday MC; Ruiz-Matus C Hum Vaccin Immunother; 2016 Aug; 12(8):2206-2214. PubMed ID: 27196006 [TBL] [Abstract][Full Text] [Related]
16. Seasonal influenza vaccination delivery through community pharmacists in England: evaluation of the London pilot. Atkins K; van Hoek AJ; Watson C; Baguelin M; Choga L; Patel A; Raj T; Jit M; Griffiths U BMJ Open; 2016 Feb; 6(2):e009739. PubMed ID: 26883237 [TBL] [Abstract][Full Text] [Related]
17. Trends in seasonal influenza vaccine distribution in the European Union: 2003-4 to 2007-8. Rodriguez de Azero M; Euro Surveill; 2008 Oct; 13(43):. PubMed ID: 18947522 [TBL] [Abstract][Full Text] [Related]
18. Financing and systems barriers to seasonal influenza vaccine delivery in community settings. Penfold RB; Rusinak D; Lieu TA; Shefer A; Messonnier M; Lee GM Vaccine; 2011 Dec; 29(52):9632-9. PubMed ID: 22036886 [TBL] [Abstract][Full Text] [Related]
19. The Rhode Island influenza vaccine experience 1995-2003: influenza vaccine price, reimbursement, availability, and Rhode Island's influenza vaccination rate. Fine M Med Health R I; 2004 Mar; 87(3):79-80. PubMed ID: 15085687 [No Abstract] [Full Text] [Related]
20. Barriers and activities to implementing or expanding influenza vaccination programs in low- and middle-income countries: A global survey. Kraigsley AM; Moore KA; Bolster A; Peters M; Richardson D; Arpey M; Sonnenberger M; McCarron M; Lambach P; Maltezou HC; Bresee JS Vaccine; 2021 Jun; 39(25):3419-3427. PubMed ID: 33992439 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]